文献速递类风湿关节炎

阿巴西普治疗类风湿关节炎患者手术安全性:法国Orencia注册数据分析

Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

基于法国Orencia类风湿关节炎注册中1012例接受阿巴西普治疗的患者,205例(20.3%)共接受263次手术,术后并发症发生率为7.2%(19次手术/19例患者)。多因素分析显示,仅阿巴西普治疗时长(每增加1个月,aOR=0.94,95%CI:0.89-0.99)和骨科手术(aOR=4.45,95%CI:1.01-20.2)与术后并发症显著相关。

要点

  • 阿巴西普治疗患者术后并发症率低(7.2%),骨科手术风险更高。
  • 阿巴西普治疗时长每增加1个月,并发症风险略降(aOR=0.94)。
  • 末次输注至手术中位间隔5.9周,与并发症无显著关联。

核心结论

  • 阿巴西普治疗RA患者术后并发症率低(7.2%),骨科手术和近期开始阿巴西普治疗与并发症风险升高相关。

研究设计与样本

  • 法国Orencia类风湿关节炎注册纳入1012例接受阿巴西普治疗的RA患者,回顾性分析其中接受手术者的术后并发症频率及危险因素。

主要发现

  • 205例(20.3%)患者共接受263次手术,其中骨科手术176次(66.9%)。
  • 19次手术(7.2%)在19例患者(9.3%)中发生并发症,包括7例伤口延迟愈合(占手术2.7%)和6例手术部位感染(占手术2.3%)。
  • 有并发症组中位每日泼尼松剂量更高[10.0(6.25-15.0)vs 6.0(5.0-10.0)mg/天,P=0.042]。
  • 多因素分析中,阿巴西普治疗时长每增加1个月,术后并发症风险降低(aOR=0.94,95%CI:0.89-0.99);骨科手术较其他手术并发症风险升高(aOR=4.45,95%CI:1.01-20.2)。

关键数值与推荐

  • 末次阿巴西普输注至手术的中位时间为5.9周(范围0.3-12.0周),有与无并发症患者间无显著差异。

临床怎么用

  • RA患者接受阿巴西普治疗期间手术并发症率较低,无需因近期输注而延迟手术;但骨科手术及近期开始阿巴西普治疗者应加强术后监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA). METHODS: The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications. RESULTS: We identified 205 (20.3%) patients who underwent 263 surgeries, including 176 (66.9%) orthopaedic surgeries. Nineteen (7.2%) surgeries, in 19 patients (9.3%), entailed complications, including 7 delayed wound healing (2.7% of surgeries) and 6 surgical site infections (2.3% of surgeries). The median time between the last infusion of ABA and surgery was 5.9 weeks (range: 0.3-12.0 weeks), with no significant difference between patients with and without complications. The median corticosteroids daily dosage was higher in the group with complications [10.0 (6.25-15.0) vs 6.0 (5.0-10.0) mg/day, P = 0.042]. In multivariate analysis, only the duration of ABA treatment was significantly associated with postoperative complications [adjusted odds ratio (aOR) = 0.94 (95% CI: 0.89, 0.99) for each month of treatment], as were orthopaedic surgeries compared with other kinds of surgery [aOR = 4.45 (95% CI: 1.01, 20.2)]. CONCLUSION: In RA patients treated with ABA, the rate of surgical complications was low: 7.2% and higher in case of orthopaedic procedure and a more recent initiation of ABA. The median time between surgery and the last infusion of ABA was short and did not influence the rate of postoperative complications.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Latourte A, Gottenberg JE, Luxembourger C, et al. Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology (Oxford). 2017. PMID: 28053274. doi:10.1093/rheumatology/kew476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。